Literature DB >> 3595916

The natural history of untreated microprolactinomas.

D A Sisam, J P Sheehan, L R Sheeler.   

Abstract

The development of radioimmunoassay (RIA) for prolactin (PRL) and sensitive high-resolution computed tomography (HRCT) has resulted in documentation of large numbers of microprolactinomas (microPRL). To try to define the rate and prevalence of tumor growth, the authors performed serial HRCT scans in 38 untreated patients, an average of 31.7 months apart. In no patient, including two patients with exuberant rises in PRL, was there any evidence of subtle tumor growth. The authors conclude that the majority of patients with microPRL have a benign course, with tumor growth occurring, if at all, over a period of years.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595916     DOI: 10.1016/s0015-0282(16)59292-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  13 in total

Review 1.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

3.  Cognitive and perceptual disturbances in a young man.

Authors:  Janos Zahajszky; Davin K Quinn; Felicia A Smith; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 4.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 5.  The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons.

Authors:  Alexander T Faje; Anne Klibanski
Journal:  Endocrine       Date:  2014-06-03       Impact factor: 3.633

6.  Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.

Authors:  Margarida Teixeira; Pedro Souteiro; Davide Carvalho
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 7.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

Review 8.  Managing prolactin-secreting adenomas during pregnancy.

Authors:  Syed Ali Imran; Ehud Ur; David B Clarke
Journal:  Can Fam Physician       Date:  2007-04       Impact factor: 3.275

9.  Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Authors:  M M Garcia; L P Kapcala
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

10.  Management of prolactinomas in Brazil: an electronic survey.

Authors:  Lucio Vilar; Luciana Ansaneli Naves; Luiz Augusto Casulari; Monalisa Ferreira Azevedo; José Luciano Albuquerque; Fabiano Marcel Serfaty; Flavia R Pinho Barbosa; Antonio Ribeiro de Oliveira; Renan Magalhães Montenegro; Renan Magalhães Montenegro; Alberto José Santos Ramos; Manuel Dos Santos Faria; Nina Rosa C Musolino; Monica R Gadelha; Cesar Luiz Boguszewski; Marcello D Bronstein
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.